Deal Activity Highlights Interest In Bispecific Antibodies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bispecific antibodies can be developed using many different formats for multiple therapeutic areas (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)). Big pharmas have inked deals with modest upfront payments to explore the use of a variety of technology applications.